320 related articles for article (PubMed ID: 29143114)
21. Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.
Rojas-Sepúlveda D; Tittarelli A; Gleisner MA; Ávalos I; Pereda C; Gallegos I; González FE; López MN; Butte JM; Roa JC; Fluxá P; Salazar-Onfray F
Cancer Immunol Immunother; 2018 Dec; 67(12):1897-1910. PubMed ID: 29600445
[TBL] [Abstract][Full Text] [Related]
22. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.
Nabekura T; Nagasawa T; Nakauchi H; Onodera M
Cancer Immunol Immunother; 2008 May; 57(5):611-22. PubMed ID: 17786440
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
24. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
[TBL] [Abstract][Full Text] [Related]
25. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
[TBL] [Abstract][Full Text] [Related]
26. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
27. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
[TBL] [Abstract][Full Text] [Related]
28. Making the most of mucin: a novel target for tumor immunotherapy.
Barratt-Boyes SM
Cancer Immunol Immunother; 1996 Nov; 43(3):142-51. PubMed ID: 9001567
[TBL] [Abstract][Full Text] [Related]
29. MMP11: a novel target antigen for cancer immunotherapy.
Peruzzi D; Mori F; Conforti A; Lazzaro D; De Rinaldis E; Ciliberto G; La Monica N; Aurisicchio L
Clin Cancer Res; 2009 Jun; 15(12):4104-13. PubMed ID: 19509157
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
31. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
32. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
33. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL; Disis ML
Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
36. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
Bryson PD; Han X; Truong N; Wang P
Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
[TBL] [Abstract][Full Text] [Related]
38. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
39. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
40. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.
Bol KF; Schreibelt G; Gerritsen WR; de Vries IJ; Figdor CG
Clin Cancer Res; 2016 Apr; 22(8):1897-906. PubMed ID: 27084743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
